Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Fiche publication
Date publication
septembre 2019
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe
Tous les auteurs :
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D,
Lien Pubmed
Résumé
The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.
Référence
N. Engl. J. Med.. 2019 Sep 30;: